According to recent studies, the targeted delivery of the chemotherapeutic agents HCPT and siMCT-4 to tumors with the help of silica nanoparticles effectively suppressed tumor growth through chemotherapy and the inhibition of lactate efflux, and this approach restored the tumor-associated macrophage (TAM) M1 phenotype and CD8+ T-cell activity in vivo, which greatly improved the tumor immune microenvironment (Li et al., 2020). This evidence concerns the gene CD8A and neoplasm.